[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

2017-2022 Global and Japan Inactivated Vaccine Market Analysis Report

August 2017 | 101 pages | ID: 297D6C38940EN
JP Research

US$ 3,085.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Inactivated Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Inactivated Vaccine market's development status and future trend in the global and Japan. It splits Inactivated Vaccine market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
  • Astellas Pharma (Japan)
  • CSL Limited (Australia)
  • Emergent BioSolutions (U.S.)
  • GlaxoSmithKline (U.K.)
  • Johnson & Johnson (U.S.)
  • MedImmune (U.S.)
  • Merck & Co (U.S.)
  • Pfizer (U.S.)
  • Sanofi Pasteur (France)
  • Serum Institute of India Pvt (India)
Geographically, this report splits the Global market into the following regions:
  • Asia Pacific
    • Japan
      • Tokyo
      • Yokohama
      • Osaka
      • Nagoya
      • Others
    • China
    • Korea
    • India
    • Others
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Russia
    • Others
  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Southeast Asia
    • Singapore
    • Malaysia
    • Vietnam
    • Myanmar
    • Thailand
    • Indonesia
    • Philippines
    • Others
  • Middle East & Africa
    • Saudi Arabia
    • Iran
    • UAE
    • Turkey
    • Israel
    • Egypt
    • South Africa
    • Others
On the basis of product, the Inactivated Vaccine market is primarily split into

By End User
  • Pediatrics
  • Adults
By Disease Indication
  • Pneumococcal
  • Influenza
  • HPV
  • Hepatitis
  • Rotavirus
Key Applications
  • Hospital
  • Medical Center
2017-2022 GLOBAL AND JAPAN INACTIVATED VACCINE MARKET ANALYSIS REPORT

1 INACTIVATED VACCINE OVERVIEW

1.1 Product Overview and Scope of Inactivated Vaccine
1.2 Global and Japan Inactivated Vaccine Market by Applications/End Users
  1.2.1 Japan Inactivated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
    1.2.1.1 Japan Inactivated Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
    1.2.1.2 Japan Inactivated Vaccine Sales Growth Rate (%) by Applications (2012-2017)
    1.2.1.3 Market Drivers and Opportunities
  1.2.2 Japan Inactivated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
  1.2.3 Global Inactivated Vaccine Sales by Application (2012-2017)
    1.2.3.1 Global Inactivated Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
    1.2.3.2 Global Inactivated Vaccine Sales Growth Rate (%) by Applications (2012-2017)
    1.2.3.3 Market Drivers and Opportunities
  1.2.4 Global Inactivated Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
  1.2.5 Hospital
  1.2.6 Medical Center
1.3 Global and Japan Market Size (Sales and Revenue) of Inactivated Vaccine (2012-2017)
  1.3.1 Japan Market Size (Sales and Revenue) of Inactivated Vaccine (2012-2017)
    1.3.1.1 Japan Inactivated Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
    1.3.1.2 Japan Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
  1.3.2 Global Market Size (Sales and Revenue) of Inactivated Vaccine (2012-2017)
    1.3.2.1 Global Inactivated Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
    1.3.2.2 Global Inactivated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
1.4 Global and Japan Classification of Inactivated Vaccine by End User
  1.4.1 Japan Inactivated Vaccine Sales (K Pcs) and Market Share by End User (2012-2017)
  1.4.2 Global Inactivated Vaccine Sales (K Pcs) and Market Share by End User (2012-2017)
  1.4.3 Japan Inactivated Vaccine Revenue (Million USD) and Market Share by End User (2012-2017)
  1.4.4 Global Inactivated Vaccine Revenue (Million USD) and Market Share by End User (2012-2017)
  1.4.5 Japan Inactivated Vaccine Price (USD/Pcs) by End User (2012-2017)
  1.4.6 Global Inactivated Vaccine Price (USD/Pcs) by End User (2012-2017)
  1.4.7 Japan Inactivated Vaccine Sales Growth Rate (%) by End User (2012-2017)
  1.4.8 Global Inactivated Vaccine Sales Growth Rate (%) by End User (2012-2017)
  1.4.9 Pediatrics
  1.4.10 Adults
1.5 Global and Japan Classification of Inactivated Vaccine by Disease Indication
  1.5.1 Japan Inactivated Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
  1.5.2 Global Inactivated Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
  1.5.3 Japan Inactivated Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
  1.5.4 Global Inactivated Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
  1.5.5 Japan Inactivated Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
  1.5.6 Global Inactivated Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
  1.5.7 Japan Inactivated Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
  1.5.8 Global Inactivated Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
  1.5.9 Pneumococcal
  1.5.10 Influenza
  1.5.11 HPV
  1.5.12 Hepatitis
  1.5.13 Rotavirus

2 GLOBAL AND JAPAN INACTIVATED VACCINE MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan Inactivated Vaccine Market Competition by Players/Manufacturers
  2.1.1 Japan Inactivated Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.1.2 Japan Inactivated Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
  2.1.3 Japan Inactivated Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
  2.1.4 Japan Inactivated Vaccine Market Competitive Situation and Trends
    2.1.4.1 Japan Inactivated Vaccine Market Concentration Rate
    2.1.4.2 Japan Inactivated Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
    2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
  2.1.5 Japan Players/Manufacturers Inactivated Vaccine Manufacturing Base Distribution, Sales Area, Product Types
2.2 Global Inactivated Vaccine Market Competition by Players/Manufacturers
  2.2.1 Global Inactivated Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.2.2 Global Inactivated Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
  2.2.3 Global Inactivated Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
  2.2.4 Global Inactivated Vaccine Market Competitive Situation and Trends
    2.2.4.1 Global Inactivated Vaccine Market Concentration Rate
    2.2.4.2 Global Inactivated Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
    2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
  2.2.5 Global Players/Manufacturers Inactivated Vaccine Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN INACTIVATED VACCINE SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Asia Pacific Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.1.1 Japan Inactivated Vaccine Sales and Revenue (2012-2017)
    3.1.1.1 Japan Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.1.2 Japan Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.1.3 Japan Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.1.2 China Inactivated Vaccine Sales and Revenue (2012-2017)
    3.1.2.1 China Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.2.2 China Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.2.3 China Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.1.3 Korea Inactivated Vaccine Sales and Revenue (2012-2017)
    3.1.3.1 Korea Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.3.2 Korea Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.3.3 Korea Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.1.4 India Inactivated Vaccine Sales and Revenue (2012-2017)
    3.1.4.1 India Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.4.2 India Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.4.3 India Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.1.5 Others Inactivated Vaccine Sales and Revenue (2012-2017)
    3.1.5.1 Others Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.5.2 Others Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.5.3 Others Inactivated Vaccine Price (USD/Pcs)(2012-2017)
3.2 Europe Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.2.1 France Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.1.1 France Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.1.2 France Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.1.3 France Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.2.2 Germany Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.2.1 Germany Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.2.2 Germany Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.2.3 Germany Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.2.3 United Kingdom Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.3.1 United Kingdom Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.3.2 United Kingdom Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.3.3 United Kingdom Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.2.4 Italy Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.4.1 Italy Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.4.2 Italy Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.4.3 Italy Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.2.5 Russia Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.5.1 Russia Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.5.2 Russia Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.5.3 Russia Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.2.6 Others Inactivated Vaccine Sales and Revenue (2012-2017)
    3.2.6.1 Others Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.6.2 Others Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.6.3 Others Inactivated Vaccine Price (USD/Pcs)(2012-2017)
3.3 North America Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.3.1 United States Inactivated Vaccine Sales and Revenue (2012-2017)
    3.3.1.1 United States Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.3.1.2 United States Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.3.1.3 United States Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.3.2 Canada Inactivated Vaccine Sales and Revenue (2012-2017)
    3.3.2.1 Canada Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.3.2.2 Canada Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.3.2.3 Canada Inactivated Vaccine Price (USD/Pcs)(2012-2017)
3.4 Latin America Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.4.1 Brazil Inactivated Vaccine Sales and Revenue (2012-2017)
    3.4.1.1 Brazil Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.1.2 Brazil Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.1.3 Brazil Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.4.2 Mexico Inactivated Vaccine Sales and Revenue (2012-2017)
    3.4.2.1 Mexico Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.2.2 Mexico Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.2.3 Mexico Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.4.3 Others Inactivated Vaccine Sales and Revenue (2012-2017)
    3.4.3.1 Others Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.3.2 Others Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.3.3 Others Inactivated Vaccine Price (USD/Pcs)(2012-2017)
3.5 Southeast Asia Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.5.1 Singapore Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.1.1 Singapore Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.1.2 Singapore Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.1.3 Singapore Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.2 Malaysia Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.2.1 Malaysia Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.2.2 Malaysia Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.2.3 Malaysia Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.3 Vietnam Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.3.1 Vietnam Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.3.2 Vietnam Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.3.3 Vietnam Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.4 Myanmar Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.4.1 Myanmar Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.4.2 Myanmar Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.4.3 Myanmar Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.5 Thailand Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.5.1 Thailand Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.5.2 Thailand Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.5.3 Thailand Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.6 Indonesia Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.6.1 Indonesia Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.6.2 Indonesia Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.6.3 Indonesia Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.7 Philippines Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.7.1 Philippines Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.7.2 Philippines Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.7.3 Philippines Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.5.8 Others Inactivated Vaccine Sales and Revenue (2012-2017)
    3.5.8.1 Others Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.8.2 Others Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.8.3 Others Inactivated Vaccine Price (USD/Pcs)(2012-2017)
3.6 Middle East & Africa Inactivated Vaccine Sales and Revenue by Regions (2012-2017)
  3.6.1 Saudi Arabia Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.1.1 Saudi Arabia Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.1.2 Saudi Arabia Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.1.3 Saudi Arabia Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.2 Iran Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.2.1 Iran Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.2.2 Iran Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.2.3 Iran Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.3 UAE Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.3.1 UAE Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.3.2 UAE Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.3.3 UAE Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.4 Turkey Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.4.1 Turkey Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.4.2 Turkey Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.4.3 Turkey Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.5 Israel Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.5.1 Israel Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.5.2 Israel Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.5.3 Israel Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.6 Egypt Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.6.1 Egypt Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.6.2 Egypt Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.6.3 Egypt Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.7 South Africa Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.7.1 South Africa Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.7.2 South Africa Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.7.3 South Africa Inactivated Vaccine Price (USD/Pcs)(2012-2017)
  3.6.8 Others Inactivated Vaccine Sales and Revenue (2012-2017)
    3.6.8.1 Others Inactivated Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.8.2 Others Inactivated Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.8.3 Others Inactivated Vaccine Price (USD/Pcs)(2012-2017)

4 GLOBAL AND JAPAN INACTIVATED VACCINE PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

4.1 Astellas Pharma (Japan)
  4.1.1 Company Basic Information, Manufacturing Base and Competitors
  4.1.2 Inactivated Vaccine Product Category, Application and Specification
    4.1.2.1 Product A
    4.1.2.2 Product B
  4.1.3 Astellas Pharma (Japan) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.1.4 Main Business/Business Overview
4.2 CSL Limited (Australia)
  4.2.1 Company Basic Information, Manufacturing Base and Competitors
  4.2.2 Inactivated Vaccine Product Category, Application and Specification
    4.2.2.1 Product A
    4.2.2.2 Product B
  4.2.3 CSL Limited (Australia) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.2.4 Main Business/Business Overview
4.3 Emergent BioSolutions (U.S.)
  4.3.1 Company Basic Information, Manufacturing Base and Competitors
  4.3.2 Inactivated Vaccine Product Category, Application and Specification
    4.3.2.1 Product A
    4.3.2.2 Product B
  4.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.3.4 Main Business/Business Overview
4.4 GlaxoSmithKline (U.K.)
  4.4.1 Company Basic Information, Manufacturing Base and Competitors
  4.4.2 Inactivated Vaccine Product Category, Application and Specification
    4.4.2.1 Product A
    4.4.2.2 Product B
  4.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.4.4 Main Business/Business Overview
4.5 Johnson & Johnson (U.S.)
  4.5.1 Company Basic Information, Manufacturing Base and Competitors
  4.5.2 Inactivated Vaccine Product Category, Application and Specification
    4.5.2.1 Product A
    4.5.2.2 Product B
  4.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.5.4 Main Business/Business Overview
4.6 MedImmune (U.S.)
  4.6.1 Company Basic Information, Manufacturing Base and Competitors
  4.6.2 Inactivated Vaccine Product Category, Application and Specification
    4.6.2.1 Product A
    4.6.2.2 Product B
  4.6.3 MedImmune (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.6.4 Main Business/Business Overview
4.7 Merck & Co (U.S.)
  4.7.1 Company Basic Information, Manufacturing Base and Competitors
  4.7.2 Inactivated Vaccine Product Category, Application and Specification
    4.7.2.1 Product A
    4.7.2.2 Product B
  4.7.3 Merck & Co (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.7.4 Main Business/Business Overview
4.8 Pfizer (U.S.)
  4.8.1 Company Basic Information, Manufacturing Base and Competitors
  4.8.2 Inactivated Vaccine Product Category, Application and Specification
    4.8.2.1 Product A
    4.8.2.2 Product B
  4.8.3 Pfizer (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.8.4 Main Business/Business Overview
4.9 Sanofi Pasteur (France)
  4.9.1 Company Basic Information, Manufacturing Base and Competitors
  4.9.2 Inactivated Vaccine Product Category, Application and Specification
    4.9.2.1 Product A
    4.9.2.2 Product B
  4.9.3 Sanofi Pasteur (France) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.9.4 Main Business/Business Overview
4.10 Serum Institute of India Pvt (India)
  4.10.1 Company Basic Information, Manufacturing Base and Competitors
  4.10.2 Inactivated Vaccine Product Category, Application and Specification
    4.10.2.1 Product A
    4.10.2.2 Product B
  4.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.10.4 Main Business/Business Overview

5 INACTIVATED VACCINE MANUFACTURING COST ANALYSIS

5.1 Inactivated Vaccine Key Raw Materials Analysis
  5.1.1 Key Raw Materials
  5.1.2 Price Trend of Key Raw Materials
  5.1.3 Key Suppliers of Raw Materials
  5.1.4 Market Concentration Rate of Raw Materials
5.2 Proportion of Manufacturing Cost Structure
  5.2.1 Raw Materials
  5.2.2 Labor Cost
  5.2.3 Manufacturing Expenses
5.3 Manufacturing Process Analysis of Inactivated Vaccine

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

6.1 Inactivated Vaccine Industrial Chain Analysis
6.2 Upstream Raw Materials Sourcing
6.3 Raw Materials Sources of Inactivated Vaccine Major Players/Manufacturers in 2016
6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

7.1 Marketing Channel
  7.1.1 Direct Marketing
  7.1.2 Indirect Marketing
  7.1.3 Marketing Channel Development Trend
7.2 Market Positioning
  7.2.1 Pricing Strategy
  7.2.2 Brand Strategy
  7.2.3 Target Client
7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

8.1 Technology Progress/Risk
  8.1.1 Substitutes Threat
  8.1.2 Technology Progress in Related Industry
8.2 Consumer Needs/Customer Preference Change
8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN INACTIVATED VACCINE MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global and Japan Inactivated Vaccine Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
9.2 Global and Japan Inactivated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
  9.2.1 by End User
  9.2.2 by Disease Indication
9.3 Global and Japan Inactivated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
9.4 Global and Japan Inactivated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

11.1 Methodology/Research Approach
  11.1.1 Research Programs/Design
  11.1.2 Market Size Estimation
  11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
  11.2.1 Secondary Sources
  11.2.2 Primary Sources
11.3 Disclaimer
11.4 Author List
LIST OF TABLES AND FIGURES

Figure Product Picture of Inactivated Vaccine
Table Japan Inactivated Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
Figure Japan Sales Market Share (%) of Inactivated Vaccine by Applications in 2016
Table Global Inactivated Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
Figure Global Sales Market Share (%) of Inactivated Vaccine by Applications in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure Pediatrics Product Picture
Figure Adults Product Picture
Figure Pneumococcal Product Picture
Figure Influenza Product Picture
Figure HPV Product Picture
Figure Hepatitis Product Picture
Figure Rotavirus Product Picture
Table Astellas Pharma (Japan) Basic Information List
Table Astellas Pharma (Japan) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Astellas Pharma (Japan) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Astellas Pharma (Japan) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Astellas Pharma (Japan) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table CSL Limited (Australia) Basic Information List
Table CSL Limited (Australia) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table CSL Limited (Australia) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table CSL Limited (Australia) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure CSL Limited (Australia) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Emergent BioSolutions (U.S.) Basic Information List
Table Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Emergent BioSolutions (U.S.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Emergent BioSolutions (U.S.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Emergent BioSolutions (U.S.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table GlaxoSmithKline (U.K.) Basic Information List
Table GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table GlaxoSmithKline (U.K.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table GlaxoSmithKline (U.K.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure GlaxoSmithKline (U.K.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Johnson & Johnson (U.S.) Basic Information List
Table Johnson & Johnson (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Johnson & Johnson (U.S.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Johnson & Johnson (U.S.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Johnson & Johnson (U.S.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table MedImmune (U.S.) Basic Information List
Table MedImmune (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table MedImmune (U.S.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table MedImmune (U.S.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure MedImmune (U.S.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Merck & Co (U.S.) Basic Information List
Table Merck & Co (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Merck & Co (U.S.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Merck & Co (U.S.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Merck & Co (U.S.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Pfizer (U.S.) Basic Information List
Table Pfizer (U.S.) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Pfizer (U.S.) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Pfizer (U.S.) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Pfizer (U.S.) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Sanofi Pasteur (France) Basic Information List
Table Sanofi Pasteur (France) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Sanofi Pasteur (France) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Sanofi Pasteur (France) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Sanofi Pasteur (France) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Serum Institute of India Pvt (India) Basic Information List
Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales Growth Rate (%)(2012-2017)
Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Serum Institute of India Pvt (India) Inactivated Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Inactivated Vaccine
Figure Manufacturing Process Analysis of Inactivated Vaccine
Figure Inactivated Vaccine Industrial Chain Analysis
Table Raw Materials Sources of Inactivated Vaccine Major Players/Manufacturers in 2016
Table Major Buyers of Inactivated Vaccine
Table Distributors/Traders List
Figure Japan Inactivated Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure Japan Inactivated Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Japan Inactivated Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
Figure Global Inactivated Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure Global Inactivated Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Inactivated Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
Table Japan Inactivated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Table Global Inactivated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Japan Inactivated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Global Inactivated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Japan Inactivated Vaccine Sales Volume Market Share Forecast by Type in 2017
Figure Global Inactivated Vaccine Sales Volume Market Share Forecast by Type in 2017
Table Japan Inactivated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
Figure Japan Inactivated Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
Figure Japan Inactivated Vaccine Sales Volume Market Share Forecast by Application in 2017
Table Global Inactivated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
Figure Global Inactivated Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Inactivated Vaccine Sales Volume Market Share Forecast by Application in 2017
Table Japan Inactivated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
Table Japan Inactivated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Figure Japan Inactivated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Table Global Inactivated Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
Table Global Inactivated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Inactivated Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories